MetLife Investment Management LLC Buys 22,334 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

MetLife Investment Management LLC lifted its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 129.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,638 shares of the life sciences company's stock after purchasing an additional 22,334 shares during the period. MetLife Investment Management LLC owned 0.05% of Integra LifeSciences worth $720,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in IART. Rubric Capital Management LP bought a new position in Integra LifeSciences during the third quarter worth about $5,325,000. Glenmede Trust Co. NA lifted its position in shares of Integra LifeSciences by 125.9% in the third quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company's stock valued at $13,224,000 after buying an additional 405,624 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Integra LifeSciences by 824.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company's stock worth $2,031,000 after acquiring an additional 99,685 shares during the period. Quantbot Technologies LP increased its holdings in shares of Integra LifeSciences by 230.5% during the 3rd quarter. Quantbot Technologies LP now owns 72,351 shares of the life sciences company's stock worth $1,315,000 after acquiring an additional 50,459 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Integra LifeSciences in the 3rd quarter valued at $198,000. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Price Performance

Shares of IART stock traded up $0.24 during trading on Friday, hitting $24.10. The company had a trading volume of 415,162 shares, compared to its average volume of 789,292. The stock's 50-day moving average price is $21.44 and its 200 day moving average price is $23.88. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The firm has a market capitalization of $1.86 billion, a P/E ratio of -267.75, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the previous year, the company posted $0.76 earnings per share. The company's quarterly revenue was down .4% on a year-over-year basis. Equities analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Insider Activity

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 3.10% of the company's stock.

Analyst Upgrades and Downgrades

IART has been the topic of several research reports. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price objective on the stock. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday, October 14th. Bank of America cut their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a research report on Monday, October 7th. BTIG Research raised Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Finally, Citigroup lifted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.